Posted by Michael Wonder on 05 Jun 2024
Nidlegy marketing authorisation application submitted to EMA
4 June 2024 - First marketing authorisation submission for Nidlegy for the treatment of locally advanced, fully resectable melanoma in the neo-adjuvant setting.
Philogen and Sun Pharma are pleased to announce the submission of a marketing authorisation application to the EMA for the approval of Nidlegy, an investigational treatment for neo-adjuvant locally advanced fully resectable melanoma.
